Profiel
Ray Lockard is currently Chief Manufacturing & Quality Officer at TScan Therapeutics, Inc., starting in 2026.
Formerly, Mr. Lockard was Executive Director-CMC, QA & External Quality at Ultragenyx Pharmaceutical, Inc. from 2020 to 2021 and Head-Site Quality at Novartis Gene Therapies, Inc. from 2019 to 2020.
Education includes an undergraduate degree from Hampden-Sydney College and an MBA from Kenan-Flagler Business School.
Actieve functies van Ray Lockard
| Bedrijven | Functie | Begin |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Corporate Officer/Principal | 01-01-2024 |
Eerdere bekende functies van Ray Lockard
| Bedrijven | Functie | Einde |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01-12-2021 |
| AVEXIS INC | Corporate Officer/Principal | 01-10-2020 |
Opleiding van Ray Lockard
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Hampden-Sydney College
Hampden-Sydney College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kenan-Flagler Business School
Kenan-Flagler Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
















